Are you or your loved ones suffering from endometrial cancer?

You may be eligible to participate in a endometrial cancer clinical trial.

Are you or your loved ones suffering from endometrial cancer? You may be eligible to participate in a endometrial cancer clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Recruiting for this study? Get access to patient recruitment tools.
Endometrial Cancer in Philadelphia PA
NCT03099499 | Phase 2 | Interventional

Are you or your loved ones suffering from endometrial cancer?

You may be eligible to participate in a endometrial cancer clinical trial.

Are you or your loved ones suffering from endometrial cancer? You may be eligible to participate in a endometrial cancer clinical trial.

Recruiting

Female

18 +

years old

This study is looking to recruit 36 Participants

ONC201 is a small molecule which selectively targets the G protein-coupled receptor DRD2. Downstream of target engagement, ONC201 activates the integrated stress response (ISR) in tumor cell leading to inactivation of Akt and extracellular signal-regulated kinase (ERK) signaling as well as induction of the TRAIL pathway. ONC201 also inhibits dopamine receptor 2 (DRD2), resulting in anti-tumor responses in preclinical models. Single agent ONC201 has been examined in open-label Phase I studies in patients with advanced, treatment refractory solid malignancies. Due to its differential anti-proliferative and pro-apoptotic response in tumor cells, treatment was overall well tolerated, and the recommended phase II dose of ONC201 was set at 625mg every three weeks. An additional dose-escalation phase I study (NCT02609230) is further evaluating weekly versus three week dosing in patients with advanced solid tumors and multiple myeloma. Preliminary data from these phase I studies suggests a possible clinical benefit in patients with advanced, chemo-refractory endometrial cancers, with at least one mixed response noted in a patient with clear cell histology. Hypothesis: Single agent ONC201 will demonstrate clinical benefit in women with recurrent or metastatic endometrial cancers, especially in those women with alterations in the Phosphoinositide 3 kinase (PI3K)/Akt/mammalian target of Rapamycin (mTOR) pathway.

Where you'll go

Selected location

Fox Chase Cancer Center

Fox Chase Cancer Center Change

333 Cottman Avenue, Philadelphia, PA, USA 19111

Gina Mantia-Smaldone, MD 215-214-1515
Gina.Mantia-Smaldone@fccc.edu

Map | Learn more
Interested in participating?
Selected location

Fox Chase Cancer Center

333 Cottman Avenue, Philadelphia, PA, USA 19111

Gina Mantia-Smaldone, MD 215-214-1515
Gina.Mantia-Smaldone@fccc.edu


The information you provide is confidential and is never sold or shared with outside vendors. By clicking the button, you agree to the PatientWing's Terms and Privacy Policy.